Stem Point Capital LP Portfolio Holdings

Stem Point Capital LP

  • $340 Billion
  • Q2 2024

Stem Point Capital LP has filed its 13F form on August 13, 2024 for Q2 2024 where it was disclosed a total value porftolio of $340 Billion distributed in 44 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Syndax Pharmaceuticals Inc with a value of $29B, Roivant Sciences Ltd. with a value of $28.7B, Immunovant, Inc. with a value of $26.7B, Crinetics Pharmaceuticals, Inc. with a value of $24.7B, and Merus N.V. with a value of $17.1B.

Examining the 13F form we can see an decrease of $38.1B in the current position value, from $378B to 340B.

Stem Point Capital LP is based out at New York, NY

Below you can find more details about Stem Point Capital LP portfolio as well as his latest detailed transactions.

Portfolio value $340 Billion
Healthcare: $293 Billion

Stock Holdings Table ETFs Only

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 44
  • Current Value $340 Billion
  • Prior Value $378 Billion
  • Filing
  • Period Q2 2024
  • Filing Date August 13, 2024
  • Form Type 13F-HR
  • Activity in Q2 2024
  • New Purchases 16 stocks
  • Additional Purchases 14 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 10 stocks
Track This Portfolio

Track Stem Point Capital LP Portfolio

Follow Stem Point Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stem Point Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Stem Point Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email